找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Immunotherapy; Aung Naing,Joud Hajjar Book 20203rd edition The Editor(s) (if applicable) and The Author(s), under exclusive license to Spr

[復(fù)制鏈接]
樓主: CHAFF
31#
發(fā)表于 2025-3-27 00:18:03 | 只看該作者
Hepatobiliary Adverse Events,city of ICI therapy. Appropriate treatment of pancreatitis still needs further investigation. Few cases, reports, and series documented cholecystitis and cholangitis as possible adverse events related to ICI therapy as well.
32#
發(fā)表于 2025-3-27 02:36:00 | 只看該作者
Cancer Imaging in Immunotherapy,g therapies, including immunotherapies, still relies on the current RECIST criteria. In this chapter, we review the traditional and new imaging response criteria for evaluation of solid tumors and briefly touch on some of the more commonly associated immunotherapy-induced adverse events.
33#
發(fā)表于 2025-3-27 08:27:10 | 只看該作者
34#
發(fā)表于 2025-3-27 12:05:48 | 只看該作者
35#
發(fā)表于 2025-3-27 17:23:54 | 只看該作者
36#
發(fā)表于 2025-3-27 20:28:24 | 只看該作者
37#
發(fā)表于 2025-3-27 22:13:00 | 只看該作者
Gastrointestinal Tract Adverse Events,ysical examination, stool tests, endoscopic and histologic evaluation, and/or imaging. Current management strategy is mainly anti-diarrheal agents for mild symptoms and immunosuppressants (e.g., corticosteroids, and infliximab or vedolizumab) for more severe diseases.
38#
發(fā)表于 2025-3-28 02:16:19 | 只看該作者
Renal Toxicity,mmune diseases and focus on renal cell cancer in setting of Chronic kidney disease (CKD). Transplant rejection in the setting of CPI use is yet to be further studied, and available data is presented in this chapter.
39#
發(fā)表于 2025-3-28 06:31:01 | 只看該作者
40#
發(fā)表于 2025-3-28 12:03:59 | 只看該作者
Advances in Diagnostic Procedures and Their Applications in the Era of Cancer Immunotherapy,n immunotherapy: immunohistochemistry, next-generation sequencing, and flow cytometry. We also describe the uses of other diagnostic procedures and preclinical animal models in cancer immunotherapy translational research.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-2-7 05:54
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
广河县| 东山县| 夹江县| 郸城县| 勃利县| 西城区| 江阴市| 肃南| 安吉县| 和硕县| 霍林郭勒市| 增城市| 永川市| 大渡口区| 宜川县| 海兴县| 民权县| 远安县| 邵阳县| 新化县| 衡东县| 通江县| 黑水县| 鄄城县| 启东市| 武威市| 盈江县| 兴安县| 长丰县| 东源县| 武功县| 普安县| 泗水县| 安丘市| 鄂尔多斯市| 文水县| 探索| 上高县| 长顺县| 华亭县| 黑山县|